Genetic Analysis

On August 21st, Genetic Analysis AS (”Genetic Analysis” or the ”Company”) announced the launch of the GA-map® Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney, Australia. The implementation marks the first placement of the Company’s microbiome testing technology in Australia. CDD is a specialist gastroenterology center recognized for its work within gastrointestinal disorders and fecal microbiota transplantation (FMT), and the test is intended to provide clinicians with a standardized tool for assessing gut microbiota composition in patients with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Analyst Group’s View on the Australian Market Entry

Genetic Analysis’ commercialization has to date been organized around three target markets, the U.S., Europe, and Asia, with the U.S. accounting for the majority of sales and Europe for most of the remainder. Australia has not previously formed part of the installed base, why Analyst Group assesses the placement as a milestone in the Company’s international expansion strategy rather than an incremental addition within an existing market. Given that the business model rests on installing the GA-map® platform at laboratories and clinics, where each installation subsequently generates recurring demand for high-margin reagent kits, entry into a new geographic market is assessed to broaden the base from which recurring revenues can be built over time. Analyst Group further considers that a first reference placement in a market typically lowers the threshold for subsequent installations, as local clinical experience and referral networks are established.

The Choice of a Leading FMT Center Validates the Market Shift Toward Diagnostics

Analyst Group assesses that the identity of the counterparty is central to the significance of the announcement. That a center whose clinical practice is built around therapeutic modulation of the microbiome adopts a standardized, CE-IVD-marked diagnostic is assessed as a concrete instance of the market shift toward a diagnostic approach that Analyst Group has described in previous coverage. The underlying logic mirrors that of the Company’s collaboration with Ferring Pharmaceuticals, where GA-map® MHI GutHealth is applied to assess baseline microbiome imbalance and monitor restoration during treatment. Where microbiome-modulating therapy is administered, objective and reproducible measurement is required both to select patients and to follow therapeutic response, and Analyst Group assesses that this dynamic is what drives clinically advanced centers toward standardized diagnostics.

Market Drivers Support Continued International Expansion

Analyst Group has consistently argued that the primary structural problem in the microbiome diagnostics market is the lack of standardization, as testing is largely conducted on research-based platforms and in-house assays with limited comparability. The GA-map® Dysbiosis Test is the only CE-IVD-marked and patented routine diagnostic test in the field, supported by more than 50 peer-reviewed publications and over 70 clinical studies. The Australian placement is assessed to follow directly from this positioning, and it also connects to the peer-reviewed publication in Gut Microbes announced in July, which demonstrated that the Dysbiosis Index remains stable across geographically diverse populations. Analyst Group assesses that documented performance independent of geography is a practical prerequisite for adoption in markets outside the Company’s established regions, and that the Australian implementation illustrates how the evidence base translates into commercial reach.

Reference Value is Assessed to Exceed the Near-Term Revenue Contribution

Adoption in the microbiome field remains characterized by long sales cycles and a gradual market shift, and Analyst Group maintains the view that installations grow steadily rather than exponentially. The value is instead assessed to lie in the reference effect and in the optionality the relationship creates, where a center focused on microbiome restoration therapy is considered a relevant candidate for the Company’s broader portfolio over time.

In summary, Analyst Group views the first Australian placement as a milestone in Genetic Analysis’ expansion strategy that opens a geographic market previously outside the Company’s footprint, and as a further validation of the shift toward standardized diagnostics in the microbiome market. That a clinically leading FMT center selects the GA-map® platform is assessed to strengthen the Company’s reference base and support subsequent placements internationally, though the financial impact is expected to accrue gradually rather than immediately.